These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 37393791)

  • 1. Fluorine in anti-HIV drugs approved by FDA from 1981 to 2023.
    Han S; Lu Y
    Eur J Med Chem; 2023 Oct; 258():115586. PubMed ID: 37393791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Advances in novel anti-HIV-1 drugs and drug candidates: 2005-2008].
    Zheng PR; Xue H; Xiao ZY; Liu G
    Yao Xue Xue Bao; 2010 Feb; 45(2):154-64. PubMed ID: 21351426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and Development of the Anti-Human Immunodeficiency Virus Drug, Emtricitabine (Emtriva, FTC).
    Liotta DC; Painter GR
    Acc Chem Res; 2016; 49(10):2091-2098. PubMed ID: 27704821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Newly approved integrase inhibitors for clinical treatment of AIDS.
    Gu WG
    Biomed Pharmacother; 2014 Oct; 68(8):917-21. PubMed ID: 25451165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How to win the HIV-1 drug resistance hurdle race: running faster or jumping higher?
    Garbelli A; Riva V; Crespan E; Maga G
    Biochem J; 2017 Apr; 474(10):1559-1577. PubMed ID: 28446620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drugs for AIDS.
    Ray S; Fatima Z; Saxena A
    Mini Rev Med Chem; 2010 Feb; 10(2):147-61. PubMed ID: 20408798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evolution and Diversity of HIV-1].
    Metzner KJ
    Praxis (Bern 1994); 2011 Jan; 100(1):29-35. PubMed ID: 21210358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening of an FDA-approved compound library identifies levosimendan as a novel anti-HIV-1 agent that inhibits viral transcription.
    Hayashi T; Jean M; Huang H; Simpson S; Santoso NG; Zhu J
    Antiviral Res; 2017 Oct; 146():76-85. PubMed ID: 28842263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorine-Containing Drugs Approved by the FDA in 2018.
    Mei H; Han J; Fustero S; Medio-Simon M; Sedgwick DM; Santi C; Ruzziconi R; Soloshonok VA
    Chemistry; 2019 Sep; 25(51):11797-11819. PubMed ID: 31099931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Target Molecules and Delivery Vehicles for Anti-HIV Drugs In vitro and In vivo.
    Bolhassani A
    Curr Pharm Des; 2018; 24(29):3393-3401. PubMed ID: 29886823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiretroviral therapeutic possibilities for human immunodeficiency virus/acquired immunodeficiency syndrome.
    Balint GA
    Pharmacol Ther; 2001 Jan; 89(1):17-27. PubMed ID: 11316511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rational approach to AIDS drug design through structural biology.
    Wlodawer A
    Annu Rev Med; 2002; 53():595-614. PubMed ID: 11818491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The development of anti-HIV-1 drugs.
    Lu XF; Chen ZW
    Yao Xue Xue Bao; 2010 Feb; 45(2):165-76. PubMed ID: 21348415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Potential of Indole Derivatives as Anti-HIV Agents: A Mini-review.
    Chen Q; Wu C; Zhu J; Li E; Xu Z
    Curr Top Med Chem; 2022; 22(12):993-1008. PubMed ID: 34636313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medicinal chemistry perspectives on the development of piperazine-containing HIV-1 inhibitors.
    Abimbola Salubi C; Abbo HS; Jahed N; Titinchi S
    Bioorg Med Chem; 2024 Feb; 99():117605. PubMed ID: 38246116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug susceptibility to etravirine and darunavir among Human Immunodeficiency Virus Type 1-derived pseudoviruses in treatment-experienced patients with HIV/AIDS in South Korea.
    Kwon OK; Kim SS; Rhee JE; Kee MK; Park M; Oh HR; Choi JY
    Virol J; 2015 Apr; 12():53. PubMed ID: 25879840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human immunodeficiency virus: The potential of medicinal plants as antiretroviral therapy.
    Shahzad M; Chen H; Akhtar T; Rafi A; Zafar MS; Zheng YT
    J Med Virol; 2022 Jun; 94(6):2669-2674. PubMed ID: 35128696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Review of FDA-Approved Anti-HIV-1 Drugs, Anti-Gag Compounds, and Potential Strategies for HIV-1 Eradication.
    Sever B; Otsuka M; Fujita M; Ciftci H
    Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nucleotide Reverse Transcriptase Inhibitors: A Thorough Review, Present Status and Future Perspective as HIV Therapeutics.
    Holec AD; Mandal S; Prathipati PK; Destache CJ
    Curr HIV Res; 2017; 15(6):411-421. PubMed ID: 29165087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current progress in the development of RNAi-based therapeutics for HIV-1.
    Zhou J; Rossi JJ
    Gene Ther; 2011 Dec; 18(12):1134-8. PubMed ID: 21956690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.